Our Pricing

Comparing Mounjaro Sulphur Burps with Other Options

Published on: June 03, 2026

If you're researching Mounjaro sulphur burps compared to other weight loss treatments, you're not alone—digestive side effects are among the most commonly reported experiences with GLP-1 receptor agonists. At Cured Pharmacy, our UK-registered clinical team helps patients understand which weight loss medication may suit their tolerance profile, with transparent pricing from £135.00 for Mounjaro and free online consultations under three minutes.

Why Mounjaro Causes Sulphur Burps: The Clinical Mechanism

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that slows gastric emptying as part of its weight loss mechanism [1]. This delayed stomach emptying allows food to remain in the digestive tract longer, which can lead to bacterial fermentation and the production of hydrogen sulphide gas—the compound responsible for the characteristic rotten egg smell of sulphur burps.

In the SURPASS clinical trial programme, gastrointestinal side effects including eructation (belching), nausea, and dyspepsia were reported in approximately 10-18% of patients on tirzepatide, with incidence varying by dose [1]. These effects typically emerge during dose escalation and often diminish as the body adapts to treatment over 4-8 weeks.

The dual-agonist action of Mounjaro—activating both GIP and GLP-1 receptors—produces more pronounced metabolic effects than single-pathway treatments, but this enhanced mechanism also increases the likelihood of gastrointestinal symptoms during the initial treatment phase [2].

Mounjaro Sulphur Burps vs Wegovy and Saxenda: A Side Effect Comparison

Wegovy (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists licensed by the MHRA for weight management in the UK. While they share a similar mechanism of slowing gastric emptying, their side effect profiles differ in frequency and severity.

In the STEP trials for semaglutide, gastrointestinal adverse events occurred in approximately 74% of participants, with nausea being most common (44%), followed by diarrhoea (30%) and vomiting (24%) [3]. Sulphur burps and eructation were reported less frequently than with tirzepatide, though individual tolerance varies considerably.

Saxenda, administered as a daily injection rather than weekly, produces more consistent but potentially prolonged gastrointestinal effects due to its shorter half-life requiring daily dosing [4]. Patients often report that nausea with Saxenda feels more persistent throughout the day, whereas Mounjaro's weekly administration may produce more intense but shorter-duration symptoms following each injection.

Which GLP-1 Treatment Has Fewer Digestive Side Effects?

Clinical trial data suggests that all GLP-1 and dual-agonist treatments carry similar gastrointestinal side effect risks, with individual response being the primary determining factor [1][3]. Some patients tolerate Mounjaro exceptionally well despite its dual mechanism, while others find semaglutide-based treatments like Wegovy gentler on their digestive system. Your UK prescriber at Cured Pharmacy can assess your medical history and previous medication tolerance to recommend the most suitable option, with all treatments requiring clinical assessment before dispensing.

How Orlistat Compares: A Different Side Effect Profile

Orlistat (available as prescription-strength 120mg or over-the-counter 60mg formulations) works through an entirely different mechanism—blocking approximately 30% of dietary fat absorption in the intestine rather than affecting appetite hormones [5]. This fundamental difference produces a distinctly different side effect profile.

Rather than sulphur burps or nausea, Orlistat commonly causes oily stools, flatulence with discharge, and faecal urgency—particularly when patients consume meals high in fat content [5]. These effects are not symptoms of intolerance but rather the expected pharmacological action of unabsorbed fat passing through the digestive system.

For patients who find GLP-1-related sulphur burps intolerable, Orlistat represents an alternative approach with different tolerability considerations. However, clinical trials demonstrate that Orlistat produces more modest weight loss outcomes (average 3-5% body weight reduction) compared to GLP-1 treatments (10-22.5% reduction) [1][5].

Choosing Between Injectable and Oral Weight Loss Treatments

Wegovy Oral Tablets (semaglutide pill) offer a non-injectable alternative for patients preferring oral administration. Early trial data suggests the oral formulation may produce slightly different gastrointestinal tolerability compared to subcutaneous injection, though comprehensive comparative studies are still emerging. At Cured Pharmacy, oral semaglutide is available from £135.00 following clinical assessment, providing another option for patients sensitive to injection-related side effects.

Evidence-Based Strategies to Reduce Mounjaro Sulphur Burps

Clinical experience with thousands of UK patients has identified several practical approaches that may help minimise sulphur burps and other digestive symptoms during Mounjaro treatment. These strategies work by reducing gastric fermentation and supporting gentler digestion.

Eating smaller, more frequent meals rather than large portions reduces the volume of food sitting in the delayed-emptying stomach, decreasing fermentation time. Avoiding high-sulphur foods such as eggs, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), red meat, and alliums (garlic, onions) during the first 6-8 weeks of treatment may significantly reduce symptom severity.

Staying well-hydrated supports gastric motility and helps flush the digestive system, while avoiding carbonated beverages reduces additional gas introduction. Some patients find that taking a probiotic supplement or consuming fermented foods supports healthier gut bacteria balance, though clinical evidence for this approach remains limited [6].

When to Contact Your Prescriber About Digestive Side Effects

Most sulphur burps and gastrointestinal symptoms with Mounjaro are transient and resolve within 4-8 weeks as the body adapts to treatment [1]. However, certain symptoms warrant clinical review to ensure safe continuation of therapy.

Contact your UK prescriber if you experience persistent vomiting (more than 24 hours), severe abdominal pain, signs of dehydration (dark urine, dizziness, reduced urination), or if digestive symptoms significantly worsen rather than improve over time. These may indicate the need for dose adjustment, slower titration, or consideration of an alternative weight loss treatment.

At Cured Pharmacy, our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073) provides ongoing support throughout your treatment journey. If side effects become problematic, we can facilitate prescriber review to optimise your medication regimen or explore alternative options such as Wegovy or Saxenda, all dispensed as genuine UK-licensed medicines.

Adjusting Your Mounjaro Dose to Improve Tolerance

The standard Mounjaro titration schedule increases the dose every four weeks, but some patients benefit from a slower escalation—remaining at each dose level for 6-8 weeks instead [1]. This extended titration allows the digestive system more time to adapt and may significantly reduce the severity of sulphur burps and nausea. Your prescriber can modify the titration schedule based on your individual tolerance and weight loss progress, balancing efficacy with side effect management.

Comparing Long-Term Tolerability: What Clinical Trials Show

Long-term adherence data from the SURPASS and STEP trial programmes provides insight into how digestive side effects evolve over extended treatment periods. In SURPASS-3, discontinuation rates due to gastrointestinal adverse events were 6.2% for tirzepatide 10mg and 7.1% for tirzepatide 15mg over 72 weeks [1].

By comparison, the STEP-1 trial reported gastrointestinal-related discontinuation in 4.5% of semaglutide 2.4mg patients over 68 weeks [3]. These similar discontinuation rates suggest that while initial symptom profiles differ between treatments, long-term tolerability is comparable across GLP-1 and dual-agonist therapies.

Importantly, most patients who continue treatment beyond the initial 12-week period report substantial improvement in digestive symptoms, with many experiencing complete resolution of sulphur burps and nausea [1][3]. This pattern supports the clinical recommendation to persist through the adaptation phase when symptoms are mild to moderate, as tolerability typically improves significantly over time.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Cani, P. D., & de Vos, W. M. (2017). Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Frontiers in Microbiology, 8, 1765. https://doi.org/10.3389/fmicb.2017.01765 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro, Wegovy, Saxenda, and prescription-strength Orlistat are prescription-only medicines in the UK and can only be dispensed following approval by a registered clinician. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications. If you experience severe or persistent side effects, contact your prescriber immediately for clinical review.